化学
生物利用度
凝血酶
职位(财务)
立体化学
直接凝血酶抑制剂的发现与发展
组合化学
药理学
内科学
财务
医学
血小板
经济
作者
Koo Lee,Cheol Won Park,Won‐Hyuk Jung,Hee Dong Park,Sun Hwa Lee,Kyung Ha Chung,Su Kyung Park,Oh-Seok Kwon,Myung-Gyun Kang,Doo-Hee Park,Sang Koo Lee,Eunice E. Kim,Suk Kyoon Yoon,Aeri Kim
摘要
Thrombin, a crucial enzyme in the blood coagulation, has been a target for antithrombotic therapy. Orally active thrombin inhibitors would provide effective and safe prophylaxis for venous and arterial thrombosis. We conducted optimization of a highly efficacious benzamidine-based thrombin inhibitor LB30812 (3, K(i) = 3 pM) to improve oral bioavailability. Of a variety of arylamidines investigated at the P1 position, 2,5-thienylamidine effectively replaced the benzamidine without compromising the thrombin inhibitory potency and oral absorption. The sulfamide and sulfonamide derivatization at the N-terminal position in general afforded highly potent thrombin inhibitors but with moderate oral absorption, while the well-absorbable N-carbamate derivatives exhibited limited metabolic stability in S9 fractions. The present work culminated in the discovery of the N-carboxymethyl- and 2,5-thienylamidine-containing compound 22 that exhibits the most favorable profiles of anticoagulant and antithrombotic activities as well as oral bioavilability (K(i) = 15 pM; F = 43%, 42%, and 15% in rats, dogs, and monkeys, respectively). This compound on a gravimetric basis was shown to be more effective than a low molecular weight heparin, enoxaparin, in the venous thrombosis models of rat and rabbit. Compound 22 (LB30870) was therefore selected for further preclinical and clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI